The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Alliance A091404: A phase II study of enzalutamide (NSC# 766085) for patients with androgen receptor-positive salivary cancers.
 
Alan Loh Ho
Consulting or Advisory Role - AstraZeneca; Ayala Pharmaceuticals; Bristol-Myers Squibb; Eisai; Genzyme; Merck; Novartis; Regeneron; Sanofi; Sun Pharma; TRM Oncology
Speakers' Bureau - Medscape; Novartis; Omniprex America
Research Funding - Allos Therapeutics; Astellas Pharma; AstraZeneca; AstraZeneca; AstraZeneca; Ayala Pharmaceuticals; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Daiichi Sankyo; Eisai; Genentech/Roche; Kolltan Pharmaceuticals; Kura Oncology; Lilly; Merck; Novartis; Novartis; Pfizer
Travel, Accommodations, Expenses - Ayala Pharmaceuticals; Ignyta; Janssen Oncology; Kura Oncology; Kura Oncology; Kura Oncology; Merck
 
Nathan R. Foster
No Relationships to Disclose
 
Alexander J. Zoroufy
No Relationships to Disclose
 
Francis P. Worden
Consulting or Advisory Role - Bristol-Myers Squibb; Loxo; Merck
Research Funding - Bristol-Myers Squibb; Eisai (Inst); Loxo; Merck (Inst); Pfizer (Inst); Progenics
 
Katharine Andress Rowe Price
No Relationships to Disclose
 
Douglas Adkins
Consulting or Advisory Role - Celgene; Lilly; Loxo; Merck; Pfizer
Research Funding - AstraZeneca; Atara Biotherapeutics; Blueprint Medicines; Bristol-Myers Squibb; Celgene; Cellceutix; Celldex; Enzychem Lifesciences; Exelis; Gliknik; Innate Pharma; Kura Oncology; Lilly; Matrix Biomed; MedImmune; Merck; Novartis; Pfizer; Polaris
 
Daniel W. Bowles
Stock and Other Ownership Interests - Bristol-Myers Squibb; Gilead Sciences
 
Hyunseok Kang
Honoraria - Cardinal Health
Consulting or Advisory Role - Genentech; Ignyta; Loxo
Research Funding - Advaxis (Inst); AstraZeneca/MedImmune (Inst); Celldex (Inst); Kura Oncology (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Kura Oncology
 
Barbara Burtness
Consulting or Advisory Role - Aduro Biotech; Alligator Bioscience; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; CUE Biopharma; Debiopharm Group; Genentech/Roche; GlaxoSmithKline; MedImmune; Merck; VentiRx
Travel, Accommodations, Expenses - Boehringer Ingelheim; Debiopharm Group; Merck
 
Eric Jeffrey Sherman
Consulting or Advisory Role - Bristol-Myers Squibb; Cota Healthcare; Eisai; Goldilocks; Loxo; Novartis
Research Funding - Eisai; Plexxikon; Roche/Genentech
 
Roscoe F. Morton
Stock and Other Ownership Interests - Newlink Genetics (I)
 
Nora Katabi
No Relationships to Disclose
 
Pamela N. Munster
Stock and Other Ownership Interests - OncoSec (I)
Honoraria - Amgen (I); Prometheus (I); Threshold Pharmaceuticals
Consulting or Advisory Role - HUYA Bioscience International
Research Funding - Andes Biotechnologies (Inst); Biomarin (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Immune Design (Inst); Intellikine (Inst); Merck (Inst); Merrimack (Inst); Nektar (Inst); Novartis (Inst); OncoMed (Inst); Onconova Therapeutics (Inst); oncosec (Inst); Pfizer (Inst); Piramal Life Science (Inst); Plexxikon (Inst); Sanofi (Inst)
 
Gary K. Schwartz
Stock and Other Ownership Interests - Abbott; Abbvie; Becton Dickinson; Bristol-Myers Squibb; GlaxoSmithKline; Johnson & Johnson; Merck; Pfizer
Honoraria - Array BioPharma; Bayer; Daiichi Sankyo; DarwinHealth; Ellipses Pharma; Fortress Biotech; Human Longevity, Inc; Iovance Biotherapeutics; Pfizer; PTC Therapeutics; PureTech
Consulting or Advisory Role - Array BioPharma; Bayer; Bionaut Labs; Daiichi Sankyo; DarwinHealth; Ellipses Pharma; Fortress Biotech; Gencirq; Human Longevity, Inc; Iovance Biotherapeutics; Pfizer; PTC Therapeutics; PureTech
Research Funding - Astex Pharmaceuticals; Calithera Biosciences (Inst); Daiichi Sankyo (Inst); Fortress Biotech (Inst); Incyte (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - Companion diagnostics for CD4 inhibitors (Inst); patent granted to develop a new technology called PNAs for cancer therapy
Travel, Accommodations, Expenses - Array BioPharma; Daiichi Sankyo; Iovance Biotherapeutics; PTC Therapeutics; PureTech